{Reference Type}: Case Reports
{Title}: Ruxolitinib Monotherapy for a Child With HAVCR2 Gene Mutation Associated Subcutaneous Panniculitis-like T-cell Lymphoma: A Case Report.
{Author}: Zhang G;Zhou C;Wei A;Zhang R;Zhao Y;Ma H;Lian H;Wang D;Wang T;
{Journal}: J Pediatr Hematol Oncol
{Volume}: 46
{Issue}: 5
{Year}: 2024 Jul 1
{Factor}: 1.17
{DOI}: 10.1097/MPH.0000000000002868
{Abstract}: <B>BACKGROUND: </B>The occurrence of hemophagocytic lymphohistiocytosis (HLH) in patients with subcutaneous panniculitis-like T-cell lymphoma (SPTCL) may be due to HAVCR2 gene mutation, leading to T-cell immunoglobulin and mucin domain-containing molecule 3 deficiency, T-cell and macrophage activation, and proinflammatory cytokine production.<BR><B>METHODS: </B>We report a patient with SPTCL and HLH for whom ruxolitinib, used as a novel treatment, showed notable therapeutic effects.<BR><B>CONCLUSIONS: </B>Remission of both HAVCR2 mutation-induced high inflammatory characteristics and significant symptoms post-ruxolitinib administration suggested that patients with SPTCL and HLH may not represent typical lymphoma cases. Ruxolitinib, with its relatively low toxic side effects, can provide favorable outcomes.